Introduction
============

Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor and has significant activity against many solid tumors when combined with chemotherapy.[@b1-ott-6-1393]--[@b3-ott-6-1393] Because bevacizumab inhibits tumor angiogenesis, which is a vital process in tumor growth and development, it induces distinguishing side effects, including hypertension, proteinuria, thromboembolism, delayed wound healing, gastrointestinal hemorrhage, bowel perforation, hemoptysis, and nasal septum perforation.[@b1-ott-6-1393],[@b4-ott-6-1393]--[@b7-ott-6-1393] Furthermore, primary tumor ulceration induced by combined therapy with bevacizumab and chemotherapy has been reported in cases of locally advanced breast cancer.[@b8-ott-6-1393] However, massive hemorrhage subsequent to rapid tumor necrosis following treatment with bevacizumab combined with paclitaxel in a primary breast cancer has not been reported to the best of our knowledge. Herein we report a case of locally advanced breast cancer that showed a rapid necrosis of the tumor and serious hemorrhage after treatment with bevacizumab combined with paclitaxel.

Case report
===========

A 27-year-old premenopausal woman with no family history of breast cancer noticed a 1-cm lump in her left breast in January 2010. Thereafter, she became pregnant, and the lump gradually increased in size to occupy her entire left breast by July. She first visited a breast clinic that referred her to the Shinshu University Hospital with suspected breast cancer. Physical examination at her initial visit revealed a hard, swollen, and erythematous left breast, with many palpable and enlarged lymph nodes in the bilateral axillae and left supraclavicular to lateral cervical region. Histopathological examination of a core needle biopsy specimen revealed invasive ductal carcinoma (scirrhous carcinoma) that was histological grade 3, estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor type 2 (HER2)-positive. A relatively high Ki-67 index (30%--40%) was also observed. Computed tomography revealed multiple metastases to the liver, mediastinal lymph nodes, and supine and pelvic bones. A final diagnosis of stage IV breast cancer was made when she had entered gestational week 24.

The patient was treated with three triweekly cycles of cyclophosphamide (500 mg/m^2^), Adriamycin® (Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan) (60 mg/m^2^), and fluorouracil (500 mg/m^2^) therapy ([Figure 1](#f1-ott-6-1393){ref-type="fig"}). A slight decrease in size of the primary tumor in the left breast was induced by this therapy; however, the multiple liver metastases enlarged. Therefore, induced delivery was planned to enable the administration of trastuzumab-based therapy. A healthy fetus was delivered through the vagina without blood transfusion at gestational week 35 in February 2011, and weekly paclitaxel (80 mg/m^2^) with trastuzumab (2 mg/kg) treatment was initiated thereafter. A partial response was observed for the liver metastases; however, the primary lesion gradually increased in size and the inflammation became exacerbated despite the new treatment. In July 2011, her treatment was changed to lapatinib and capecitabine as a third-line therapy. The size of the primary tumor decreased slightly and its progression was temporarily inhibited. Although the multiple liver metastases were successfully controlled by these therapies, the primary tumor began to enlarge again in December 2011. Thereafter, treatment was changed to weekly trastuzumab (2 mg/kg on days 1, 8, and 15) and vinorelbine (25 mg/m^2^ on days 1 and 8) as a fourth-line therapy; however, almost no clinical response was observed. Therefore, in January 2012, a fifth-line combination therapy was initiated with docetaxel (75 mg/m^2^ on day 1) and carboplatin (6 area under the curve \[AUC\] on day 1) plus trastuzumab (2 mg/kg on days 1, 8, and 15). This treatment also had to be discontinued after one cycle because of marked anorexia. In the meantime, the primary tumor grew rapidly and extended beyond the skin in April 2012. To inhibit this growth, eribulin (1.4 mg/m^2^) was initiated as a sixth-line therapy; however, she was readmitted with dyspnea due to massive left pleural effusion after one cycle. By that time, the size of the primary tumor had increased to 15 × 12 × 9 cm, and its surface had become nodular and partially erosive.

As it was considered that the primary tumor became resistant to anti-HER2-based therapy, combination therapy with paclitaxel (90 mg/m^2^ on days 1, 8, and 15) and bevacizumab (10 mg/m^2^ on days 1 and 15) was initiated as a seventh-line therapy after removal of the pleural effusion by thoracocentesis ([Figure 2](#f2-ott-6-1393){ref-type="fig"}). Three days after the first infusion of paclitaxel and bevacizumab, the volume of the primary tumor occupying her entire left breast began to decrease and its color turned to dusky red, followed by spread of skin erosion. The entire mass flattened drastically because of rapid tumor necrosis. Next, the erosion developed deep ulceration and necrosis, with loss of all skin layers over an extensive area. This led to exposure of the underlying pectoralis major muscles by the end of the first cycle of treatment. Gradually, most of the tumor became necrotic and a large area of the pectoralis major muscle was exposed, with the remaining tumor at the rim of the ulcerated lesion 4 weeks after bevacizumab initiation.

Six days after initiation of the second treatment cycle, she was readmitted to our hospital because of massive hemorrhage from the surface of the necrotic residual tumor in her left breast. Hemostasis was achieved by applying pressure with gauze and oxidized cellulose. To prevent further hemorrhage, the surface of the residual tumor was covered and compressed firmly with thick gauze; however, massive hemorrhage occurred again on the following day, necessitating several hours of manual compression. The total blood loss during these 2 days was approximately 1,800 mL; therefore, she required 560 mL of leukocyte-reduced red cell concentrate transfusion on the first day and an additional 280 mL on the following day. The bleeding from the ulcerated tumor finally ceased. The combination therapy of paclitaxel and bevacizumab was discontinued and local treatment of the ulcerated lesion was continued. Because the ulcerated lesion caused severe pain, both opioid and nonopioid analgesics were administered. The patient desired to be with her family; therefore, she was discharged after 2 weeks of hospitalization. Thereafter, she visited our hospital daily for local treatment. Because of the lack of healing in the large ulcerated lesion as well as the patient's request for temporary cessation of anticancer therapy, only local treatment was administered. Twelve days after discharge, however, her respiratory status suddenly deteriorated and she experienced cardiopulmonary arrest in the ambulance en route to the hospital. Cardiopulmonary resuscitation was unsuccessful and the patient eventually succumbed. Although an autopsy was not performed, we considered that she died from respiratory failure caused by carcinomatous lymphangitis as determined by a chest X-ray.

Discussion
==========

Several reports have demonstrated the adverse event of hemorrhage in patients with breast cancer treated with bevacizumab;[@b8-ott-6-1393]--[@b10-ott-6-1393] however, to the best of our knowledge, none have described rapid primary tumor necrosis accompanied by massive hemorrhage that required blood transfusion in response to this drug. Therefore, this is the first report to describe massive hemorrhage caused by bevacizumab-based treatment for a primary breast tumor.

Adverse events of bleeding, including major pulmonary hemorrhage associated with squamous cell histology, cavitated or necrotic tumors, and tumors located close to major blood vessels, have been noted in cases of lung cancer. Furthermore, because tumor-associated hemorrhage may become fatal, squamous cell lung cancer or a centrally located lung tumor is contraindicated for bevacizumab-based treatment.[@b11-ott-6-1393],[@b12-ott-6-1393] With regard to breast cancer, fatal massive hemorrhage 3 days after the administration of bevacizumab and paclitaxel was reported in a patient with multiple lung metastases localized close to a blood vessel.[@b9-ott-6-1393] As evidenced in the present and referenced cases, bevacizumab should be administrated very cautiously in patients with breast cancer accompanied by centrally located lung metastases.

Cottu et al reported that six of 12 consecutive advanced breast cancer patients with extensive skin involvement who were treated with bevacizumab-based therapy showed a transformation from skin erosion to deep ulceration and necrosis, with loss of all skin layers over an extensive area and exposure of underlying fat and muscle tissues.[@b8-ott-6-1393] However, severe hemorrhage from the ulcerated tumor was not observed in their case series. Our patient experienced a similar transformation from skin erosion to deep ulceration and necrosis followed by massive hemorrhage. Although fatal hemorrhage from a primary tumor is recognized as a critical complication in patients with colon and lung cancer, possible massive hemorrhage from a primary breast cancer lesion should not be overlooked. Our case demonstrated that a primary breast cancer lesion with skin involvement also has the potential of fatal hemorrhage following administration of bevacizumab-based treatment.

In our patient, the large ulcerated lesion showed no healing tendency. Cottu et al reported a long-term delay in wound healing in several cases once necrosis occurred after bevacizumab discontinuation.[@b8-ott-6-1393] Furthermore, healing of the flap was substantially delayed in patients who underwent surgery aimed at complete resection of skin lesions after the washout of bevacizumab for at least 4 weeks, while complete healing of the flap was not achieved in two patients. An adverse event, such as that in the present case, considerably impairs the patient's quality of life; therefore, careful assessment of the skin lesion is recommended before initiated bevacizumab-based treatment. On the other hand, Lazzati et al reported impaired wound healing and flap necrosis after mastectomy in a case of advanced breast cancer treated with neoadjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy followed by weekly paclitaxel combined with bevacizumab.[@b13-ott-6-1393] In that case, although surgery was performed 6 weeks after the last administration of bevacizumab, skin necrosis occurred within the center of the wound 2 days after surgery. Moreover, histopathological examination revealed vascular thrombosis with dermal and subdermal infarctions in the excised skin, indicating that bevacizumab inhibits angiogenesis required for wound healing long after its discontinuation. Therefore, the indications of bevacizumab should be carefully considered before initiating the treatment of patients with locally advanced breast cancer scheduled for surgery.

In 2011, the US Food and Drug Administration excluded metastatic breast cancer as an indication of bevacizumab because it did not improve overall patient survival. However, a meta-regression analysis of five clinical trials showed that bevacizumab combined with chemotherapy for advanced breast cancer significantly improved progression-free survival when used as a first-line therapy.[@b14-ott-6-1393] With regard to the effect of bevacizumab for HER2-positive breast cancer, the results of BEVERLY- 2 trial have recently been published. In this Phase II trial, the efficacy and safety of neoadjuvant bevacizumab combined with trastuzumab and chemotherapy in patients with primary HER2-positive inflammatory breast cancer were assessed, and 63.5% of patients showed a pathological complete response with the combination therapy without serious adverse events.[@b15-ott-6-1393] As for the treatment of HER2-positive metastatic breast cancer, a combination of bevacizumab with trastuzumab and docetaxel as the first-line therapy showed a longer progression-free survival in the bevacizumab arm than that in the non-bevacizumab arm, although the benefit was not statistically significant. Thus, bevacizumab-containing treatments have demonstrated promising results in HER2-positive breast cancer.[@b16-ott-6-1393] In addition, as shown in the present case report, bevacizumab combined with chemotherapy can induce shrinkage of locally advanced breast cancer followed by drastic necrosis in a manner different from that when conventional cytotoxic agents are used. Therefore, bevacizumab exerts obvious potent and targeted activity against a subgroup of breast cancers. Nonetheless, further investigations are required to develop biomarkers that can predict tumor response to bevacizumab. Before administering bevacizumab in the treatment of locally advanced breast cancer, physicians should be aware of this drug's potential to severely impair quality of life by causing deep ulcerations of the skin and soft tissues as well as massive tumor hemorrhage.
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![The patient's clinical course before administration of paclitaxel and bevacizumab.\
**Notes:** The line graph shows changes in tumor markers and serum Her2 (human epidermal growth factor receptor type 2) and indicates the individual treatments (**A**). Macroscopic and computed tomography findings of the primary tumor/multiple liver metastases (**B**). \*represents the childbirth delivery day.\
**Abbreviations:** Ca15-3, cancer antigen 15-3; CAF, cyclophosphamide, adriamycin, and 5-fluorouracil therapy; CEA, carcinoembryonic antigen; E, eribulin; TCH, docetaxel, carboplatin, and trastuzumab; tras, trastuzumab; Vino, vinorelbine.](ott-6-1393Fig1){#f1-ott-6-1393}

![The patient's clinical course after administration of paclitaxel and bevacizumab combination therapy.\
**Notes:** (**A** and **B**) show the findings of the primary tumor in the first and second course of the treatment, respectively. The inverted triangles (▼) indicate the massive hemorrhage.\
**Abbreviations:** B, bevacizumab; p, paclitaxel.](ott-6-1393Fig2){#f2-ott-6-1393}
